Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2602
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBatyodlu, Figen-
dc.contributor.authorDemirel, Sibel-
dc.contributor.authorOzmert, Emin-
dc.contributor.authorUzun, Aslihan-
dc.contributor.authorYalcindag, Fatime Nilufer-
dc.date.accessioned2022-08-17T06:51:21Z-
dc.date.available2022-08-17T06:51:21Z-
dc.date.issued2017-
dc.identifier.urihttp://doi.org/10.3109/09273948.2015.1108445-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.3109/09273948.2015.1108445-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2602-
dc.description.abstractPurpose: To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD). Methods: In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL). Results: The mean anterior chamber flare was 10.7 +/- 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 +/- 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 +/- 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05). Conclusions: No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.en_US
dc.language.isoengen_US
dc.publisherTAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USAen_US
dc.relation.isversionof10.3109/09273948.2015.1108445en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAge-related macular degeneration; anterior chamber; aqueous flare; intravitreal injection; ranibizumaben_US
dc.subjectINTRAOCULAR INFLAMMATION; BEVACIZUMAB; OUTCOMES; ANCHORen_US
dc.titleEvaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degenerationen_US
dc.typearticleen_US
dc.relation.journalOCULAR IMMUNOLOGY AND INFLAMMATIONen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0002-5787-3879en_US
dc.contributor.authorID0000-0002-6430-6565en_US
dc.identifier.volume25en_US
dc.identifier.issue2en_US
dc.identifier.startpage229en_US
dc.identifier.endpage232en_US
Appears in Collections:Cerrahi Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.